Dompe International SA, of Lausanne, Switzerland, said its recombinant human nerve growth factor (rhNGF) was designated an orphan drug by the FDA for the treatment of neurotrophic keratitis, a degenerative corneal disease that affects less than one in 5,000 people and is currently without a cure.